neurobopharma.com (NRBO): Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization
The price indicator on the NeuroBo Pharmaceuticals (NRBO) chart demonstrates a metric at , which is relevant for a biotech firm developing obesity and diabetes treatments for long-term earnings under patent protection. NeuroBo Pharmaceuticals also invests in neuron regeneration and the fight against metabolic pathologies. Expectations for interim trials of new drugs and partnerships with corporate behemoths support the increase in value.
NRBO (NeuroBo): analytical breakdowns and indicator data
- stock price and consensus target price:
- stock exchange capitalization data:
- book value of equity indicators:
- debt and solvency information:
Debt to Equity NeuroBo Pharmaceuticals|NRBO - Long-Term Liabilities to Capital|Short-Term Debt to Equity Ratio NeuroBo|NRBO - Aggregate Debt Obligations|Debt to Book Capitalization Ratio NeuroBo Pharmaceuticals|NRBO - Long-Term Liabilities|Company Short-Term Debts NeuroBo Pharmaceuticals|Quick Ratio neurobopharma.com
- business earnings and investment ratios data:
NRBO - Net Profit|Expected Profit NeuroBo Pharmaceuticals|NRBO - Company Value to Net Income|Future Price to Earnings NeuroBo Pharmaceuticals Inc|NRBO - Price/Earnings to Growth Multiple|EV/EBITDA Multiple NeuroBo Pharmaceuticals|NRBO - Operating profit EBITDA|Net earnings per share (EPS TTM) NeuroBo Pharmaceuticals|NRBO - Net earnings per share for the last 12 months|Quarterly EPS earnings growth neurobopharma.com|NRBO - Earnings per share growth rate in current year|Expected earnings per share growth for next year NeuroBo Pharmaceuticals
- revenue and sales details:
Summary company analysis:NRBO (NeuroBo)
The EV/EBITDA multiple compares the total enterprise value, including net debt, against operating profit to determine the pre-tax payback period of assets. For NeuroBo Pharmaceuticals (NRBO), this metric is critical, as geopolitical supply chain disruptions and trial delays directly impact EBITDA. By analyzing the historical EV/EBITDA ratio of the business, an investor can distinguish fundamental undervaluation from a systemic liquidity crisis within the company.
Direct competitors
Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Biogen Inc BIIB|EV/EBITDA Multiple neurocrine.com NBIX|RGC - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA Axsome|ACAD: EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation XENE|VKTX (Viking Therapeutics Corp) - EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation SUPN (Supernus)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Catalyst Pharma (CPRX)|DNLI (Denali Therapeutics Inc) - Business Value to Operating Income Before Depreciation|Harmony Pharma - Enterprise Value to EBITDA Ratio|BHVN: Enterprise Value to Operating Income Before Depreciation|Amylyx Pharmaceuticals - EV/EBITDA Multiple|Company Value to EBITDA trevitherapeutics.com|PRAX: EV/EBITDA Multiple|Company Value to Operating Income Before Depreciation Ratio AVXL (Anavex Life Sciences Corp.)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization CeriBell, Inc.|Company Value to EBITDA Prothena Biosciences PRTA|Enterprise Value to EBITDA Ratio ALEC (Alector Therapeutics)|Total Company Value to Operating Income Before Depreciation Ratio Annexon, Inc.|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Omeros Corporation OMER|NGNE - Enterprise Value to EBITDA Ratio|ACIU - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio VYGR|NMRA: EV/EBITDA Multiple|Scilex Holding Company - Business Value to Operating Income Before Depreciation|TVGN (Tevogen Bio Holdings, Inc.) - EV/EBITDA Multiple|EV/EBITDA Multiple Alpha Cognition|EV/EBITDA Multiple CGTX|IKT - Company Value to EBITDA|EV/EBITDA Multiple SAVA (cassavasciences.com)|Business Value to Operating Income Before Depreciation ASRT|Coya Therapeutics Inc - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio vistagen.com VTGN|Ovid Therapeutics Inc. (OVID) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Acumen Pharmaceuticals, Inc (ABOS) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization CervoMed Inc.|Alterity Therapeutics (ATHE) - Total Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple CLNN|PEPG - Company Value to EBITDA|EV/EBITDA Multiple JUNS (Jupiter Neurosciences, Inc.)|RLMD - Enterprise Value to EBITDA Ratio|ANVS - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Multiple Grace Therapeutics (GRCE)|AIFF: EV/EBITDA Multiple|ANEW Medical, Inc. (KLTO) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization NeuroSense Therapeutics Ltd.|RVPH: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple MTVA|EV/EBITDA Multiple NeurAxis (NRXS)|Helius Medical Technologies, Inc. - Enterprise Value to EBITDA Ratio|Total Company Value to Operating Income Before Depreciation Ratio Passage Bio, Inc. (PASG)|Neuphoria - EV/EBITDA Multiple|Business Value to Operating Income Before Depreciation NERV (Minerva)|ATHA: EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation ADXN|Enterprise Value to EBITDA Ratio ALZN|Company Value to EBITDA Cyclerion Therapeutics CYCN|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Protagenic Therapeutics (PTIX)|EV/EBITDA Multiple Pasithea Therapeutics Corp (KTTA)|Cortigent, Inc. - Enterprise Value to EBITDA Ratio|EV/EBITDA Multiple Avenue Therapeutics ATXI|BCLI - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Business Value to Operating Income Before Depreciation CARA (Cara Therapeutics)|Chromocell Therapeutics Corporation (CHRO) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Eliem Therapeutics, Inc. - Business Value to Operating Income Before Depreciation|Enterprise Value to EBITDA Ratio ITCI|Company Value to EBITDA longboardpharma.com LBPH|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Marinus (MRNS)|Enterprise Value to Operating Income Before Depreciation Ratio NKGN|EV/EBITDA Multiple SAGE (Sage Therapeutics, Inc)|SNPX: Enterprise Value to Operating Income Before Depreciation|Trevena Inc. - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio vigilneuro.com VIGL|WENA: EV/EBITDA Multiple|Company Value to EBITDA Cerevel Therapeutics Inc (CERE)
